ProPublica

Journalism in the Public Interest

Cancel

Prescriber Checkup

Prescriber Checkup » Michigan » Hematology Oncology

Top Hematology Oncology Prescribers in Michigan

Top Prescribers

Providers are grouped by the primary specialty they listed when applying for a national health ID number. This doesn’t necessarily mean the person has special training or certification. Specialty is self-reported by providers and may have changed. Patients and claims shown are for Medicare Part D only.

Prescriber Claims Filled Total Cost Medicare Part D Patients Claims for Brand Name Drugs Schedule Two Schedule Three Dangerous Drugs to Seniors Brand Name Drugs Prescription Price
SUSAN HAROLD MD

Hematology Oncology

6,551

$657K

199
122 are 65+

0%
patients receiving schedule two controlled substances

Avg: 11%

21%
patients receiving schedule three controlled substances

Avg: 15%

0%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 1%

28%
prescriptions for brand name drugs

Avg: 19%

$100
Average prescription price

Avg: $433

AMBUJAM KRISHNAN MD

Hematology Oncology

5,584

$547K

203
179 are 65+

0%
patients receiving schedule two controlled substances

Avg: 11%

18%
patients receiving schedule three controlled substances

Avg: 15%

1%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 1%

23%
prescriptions for brand name drugs

Avg: 19%

$98
Average prescription price

Avg: $433

LOUIS WULFEKUHLER MD

Hematology Oncology

4,338

$192K

227
59 are 65+

0%
patients receiving schedule two controlled substances

Avg: 11%

46%
patients receiving schedule three controlled substances

Avg: 15%

0%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 1%

23%
prescriptions for brand name drugs

Avg: 19%

$44
Average prescription price

Avg: $433

BHARAT AGRAWAL MD

Hematology Oncology

4,127

$433K

152
131 are 65+

10%
patients receiving schedule two controlled substances

Avg: 11%

19%
patients receiving schedule three controlled substances

Avg: 15%

1%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 1%

26%
prescriptions for brand name drugs

Avg: 19%

$105
Average prescription price

Avg: $433

MARCIA LIEPMAN MD

Hematology Oncology

3,438

$992K

390
291 are 65+

15%
patients receiving schedule two controlled substances

Avg: 11%

21%
patients receiving schedule three controlled substances

Avg: 15%

1%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 1%

15%
prescriptions for brand name drugs

Avg: 19%

$289
Average prescription price

Avg: $433

BHADRESH NAYAK MD

Hematology Oncology

3,363

$396K

262
230 are 65+

11%
patients receiving schedule two controlled substances

Avg: 11%

23%
patients receiving schedule three controlled substances

Avg: 15%

2%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 1%

18%
prescriptions for brand name drugs

Avg: 19%

$118
Average prescription price

Avg: $433

XIUSHENG QIN M.D., PH.D.

Hematology Oncology

3,137

$543K

293
227 are 65+

15%
patients receiving schedule two controlled substances

Avg: 11%

25%
patients receiving schedule three controlled substances

Avg: 15%

2%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 1%

12%
prescriptions for brand name drugs

Avg: 19%

$173
Average prescription price

Avg: $433

STEPHEN SMILEY MD

Hematology Oncology

3,069

$1.36M

344
277 are 65+

12%
patients receiving schedule two controlled substances

Avg: 11%

22%
patients receiving schedule three controlled substances

Avg: 15%

3%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 1%

16%
prescriptions for brand name drugs

Avg: 19%

$442
Average prescription price

Avg: $433

EFSTATHIOS TAPAZOGLOU M.D.

Hematology Oncology

3,000

$505K

288
227 are 65+

5%
patients receiving schedule two controlled substances

Avg: 11%

18%
patients receiving schedule three controlled substances

Avg: 15%

3%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 1%

19%
prescriptions for brand name drugs

Avg: 19%

$168
Average prescription price

Avg: $433

FARID FATA M.D.

Hematology Oncology

2,935

$1.44M

338
279 are 65+

15%
patients receiving schedule two controlled substances

Avg: 11%

19%
patients receiving schedule three controlled substances

Avg: 15%

2%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 1%

21%
prescriptions for brand name drugs

Avg: 19%

$492
Average prescription price

Avg: $433

CAROL PETERSON M.D.

Hematology Oncology

2,856

$1.01M

279
226 are 65+

17%
patients receiving schedule two controlled substances

Avg: 11%

20%
patients receiving schedule three controlled substances

Avg: 15%

3%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 1%

20%
prescriptions for brand name drugs

Avg: 19%

$353
Average prescription price

Avg: $433

EDMUND PALOYAN M.D.

Hematology Oncology

2,325

$620K

308
239 are 65+

13%
patients receiving schedule two controlled substances

Avg: 11%

25%
patients receiving schedule three controlled substances

Avg: 15%

1%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 1%

13%
prescriptions for brand name drugs

Avg: 19%

$267
Average prescription price

Avg: $433

JEFFREY MARGOLIS M.D.

Hematology Oncology

2,217

$1.38M

353
302 are 65+

8%
patients receiving schedule two controlled substances

Avg: 11%

12%
patients receiving schedule three controlled substances

Avg: 15%

1%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 1%

20%
prescriptions for brand name drugs

Avg: 19%

$622
Average prescription price

Avg: $433

JITENDER JAIN M.D.

Hematology Oncology

2,183

$90.1K

99
75 are 65+

0%
patients receiving schedule two controlled substances

Avg: 11%

38%
patients receiving schedule three controlled substances

Avg: 15%

1%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 1%

17%
prescriptions for brand name drugs

Avg: 19%

$41
Average prescription price

Avg: $433

FIKRY IBRAHIM MD

Hematology Oncology

1,911

$118K

50
41 are 65+

0%
patients receiving schedule two controlled substances

Avg: 11%

22%
patients receiving schedule three controlled substances

Avg: 15%

1%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 1%

24%
prescriptions for brand name drugs

Avg: 19%

$62
Average prescription price

Avg: $433

RIZWAN DANISH MD

Hematology Oncology

1,787

$821K

241
176 are 65+

15%
patients receiving schedule two controlled substances

Avg: 11%

21%
patients receiving schedule three controlled substances

Avg: 15%

3%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 1%

18%
prescriptions for brand name drugs

Avg: 19%

$459
Average prescription price

Avg: $433

KENNETH TUCKER MD

Hematology Oncology

1,752

$191K

124
104 are 65+

0%
patients receiving schedule two controlled substances

Avg: 11%

31%
patients receiving schedule three controlled substances

Avg: 15%

1%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 1%

16%
prescriptions for brand name drugs

Avg: 19%

$109
Average prescription price

Avg: $433

ROMAN FRANKLIN M.D.

Hematology Oncology

1,696

$1.32M

185
135 are 65+

10%
patients receiving schedule two controlled substances

Avg: 11%

6%
patients receiving schedule three controlled substances

Avg: 15%

1%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 1%

41%
prescriptions for brand name drugs

Avg: 19%

$775
Average prescription price

Avg: $433

KEITH BAILEY MD

Hematology Oncology

1,656

$681K

192
158 are 65+

15%
patients receiving schedule two controlled substances

Avg: 11%

16%
patients receiving schedule three controlled substances

Avg: 15%

1%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 1%

19%
prescriptions for brand name drugs

Avg: 19%

$411
Average prescription price

Avg: $433

JOHN BARTNIK M.D.

Hematology Oncology

1,509

$1.37M

236
191 are 65+

14%
patients receiving schedule two controlled substances

Avg: 11%

15%
patients receiving schedule three controlled substances

Avg: 15%

3%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 1%

21%
prescriptions for brand name drugs

Avg: 19%

$907
Average prescription price

Avg: $433

MICHAEL ZAKEM D.O.

Hematology Oncology

1,407

$1.23M

226
182 are 65+

9%
patients receiving schedule two controlled substances

Avg: 11%

13%
patients receiving schedule three controlled substances

Avg: 15%

0%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 1%

19%
prescriptions for brand name drugs

Avg: 19%

$873
Average prescription price

Avg: $433

GEORGE HOWARD M.D.

Hematology Oncology

1,342

$954K

215
166 are 65+

13%
patients receiving schedule two controlled substances

Avg: 11%

20%
patients receiving schedule three controlled substances

Avg: 15%

1%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 1%

24%
prescriptions for brand name drugs

Avg: 19%

$711
Average prescription price

Avg: $433

ROBERT SCHWERT DO

Hematology Oncology

1,339

$612K

205
168 are 65+

11%
patients receiving schedule two controlled substances

Avg: 11%

15%
patients receiving schedule three controlled substances

Avg: 15%

3%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 1%

18%
prescriptions for brand name drugs

Avg: 19%

$457
Average prescription price

Avg: $433

LYLE GOLDMAN MD

Hematology Oncology

1,324

$670K

195
165 are 65+

0%
patients receiving schedule two controlled substances

Avg: 11%

14%
patients receiving schedule three controlled substances

Avg: 15%

1%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 1%

19%
prescriptions for brand name drugs

Avg: 19%

$506
Average prescription price

Avg: $433

CHRISTOPHER REYNOLDS MD

Hematology Oncology

1,235

$1.01M

183
140 are 65+

12%
patients receiving schedule two controlled substances

Avg: 11%

9%
patients receiving schedule three controlled substances

Avg: 15%

0%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 1%

15%
prescriptions for brand name drugs

Avg: 19%

$816
Average prescription price

Avg: $433

Sources

Centers for Medicare and Medicaid Services; National Technical Information Service; First Databank